6533b832fe1ef96bd129abcd

RESEARCH PRODUCT

Longitudinal data from the international registry for Niemann-Pick disease type C (NPC)

Harir DrevonAudrey MullerMarc C. PattersonEugen MengelMarie T. VanierFrits A. WijburgMercè PinedaB. Schwierin

subject

Pediatricsmedicine.medical_specialtyNiemann–Pick disease type CLongitudinal databusiness.industryEndocrinology Diabetes and MetabolismChronic diarrhoeamedicine.diseaseBiochemistryEndocrinologyTolerabilityMiglustatGeneticsMedicinebusinessMolecular Biologymedicine.drug

description

(0.69) years. Among 74/80 patients with available data, 10 (14%) patients had early-infantile (aged b2 years), 24 (32%) late-infantile (2 to b6 years), 24 (32%) juvenile (6 to b15 years), and 16 (22%) adolescent/ adult (≥15 years) onset of neurological manifestations. Mean (95%CI) composite disability scores at enrolment and last follow-up visit were 0.39 (0.34, 0.45; N = 75) and 0.45 (0.39, 0.51; N = 76), respectively. A total of 52/72 (72%) patients were categorised as ’improved/stable’ ;2 0/ 72 (28%) were categorised as ‘progressed’. Safety and tolerability findings for miglustat were in line with previous published data. A low proportion of patients had chronic diarrhoea during follow up (7.6%). Disability status was improved or stable in the majority of miglustattreated patients.

https://doi.org/10.1016/j.ymgme.2013.12.203